Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
Adds graphic, updates shares, adds conference call details in paragraphs 6 and 15
By Patrick Wingrove
Nov 12 (Reuters) -Novavax NVAX.O cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi SASY.PA.
Shares of the U.S. biotech firm fell 3% to $8.73.
The U.S. vaccine maker now expects between $175 million and $225 million for full-year sales of its COVID vaccine, its only product on the market, down from the $275 million to $375 million it previously forecast.
"We were hopeful to get a larger market share this year," NovavaxCEO John Jacobs said in an interview, adding the company was averaging about 3% of the market weekly.
If the company doesn't see the sales trend turn more positive in the current quarter, Jacobs said, "we would be under what we were hoping to get in the U.S. on revenue, so we took that number down to be conservative."
Jacobs said on a post-earnings conference call that for the 2024-25 vaccination season, the total U.S. market could be about 40 million to 50 million COVID shots, based on current trends.
The company also cut its sales projection when it reported second-quarter earnings in August.
Novavax's COVID vaccine brought in sales of $38.21 million for the third quarter, ahead of analysts' average expectations of $29 million, according to LSEG data.
Total revenue for the quarter was $84.51 million, beating analysts' expectations of $65.78 million, but down nearly 55% from the previous year.
Novavax also cut its 2024 total revenue forecast to between $650 million and $700 million, from $700 million to $800 million previously. At the start of the year, the companysaid it expected to make as much as $1 billion in revenue.
Jacobs acknowledged that Novavax does not have the market leverage and scale of French drugmaker Sanofi, with which it signed a licensing deal earlier this year to sell its COVID vaccine from 2025 in several markets, including the U.S. and Europe.
Novavax has struggled to keep pace with rival vaccine makers Moderna MRNA.O and Pfizer PFE.N, which reported more than $3 billion in combined sales for their mRNA COVID shots for the third quarter.
The company is banking on revenue from its Sanofi deal and vaccines in development, including an experimental COVID-flu combination shot, which Novavax said this week gotthe green light from the U.S. FDAto resume clinical testing.
Novavax does not expect a significant impact from the clinical hold and plans to start the late-stage trial as soon as possible.
It posteda net loss of $121 million for the quarter, less than the loss of $133 million estimated by analysts. It said it ended the quarter with $1 billion in cash and receivables.
Novavax https://reut.rs/3YZPygL
Reporting by Patrick Wingrove; Additional reporting by Bhanvi Satija and Puyaan Singh in Bengaluru;
Editing by Bill Berkrot and Devika Syamnath
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
